Cycling to cancer with cyclin D1.
Genetic aberrations in the regulatory circuits that govern transit through the G(1) phase of the cell cycle occur frequently in human cancer and overexpression of the G(1) phase cyclin, cyclin D1, is one of the most commonly observed alterations. Cyclin D1 accumulates and activates its cognate CDK (CDK4/6) in response to mitogenic growth factors in early to mid G(1) phase. The resulting cyclin D1-dependent kinase initiates the phosphorylation-dependent inactivation of the retinoblastoma tumor suppressor protein. Mitogen-dependent activation of the cyclin D1 kinase occurs through increased transcription, protein accumulation, cyclin/CDK assembly, reduced cyclin proteolysis, and decreased nuclear export. Perturbations at any step, which result in reduced growth factor requirements for cyclin D1/CDK activation, will provide cells with a distinct growth advantage over their normal counterparts and thus likely represents an early event in neoplasia.
Diehl
J Alan
JA
The Leonard and Madlyn Abramson Family Cancer Research Institute, University of Pennsylvania Cancer Center, Department of Cancer Biology, Philadelphia, Pennsylvania 19104 USA. adiehl@mail.med.upenn.edu.
D000970:Antineoplastic Agents / Q000627:therapeutic use; D019938:Cyclin D1 / Q000037:antagonists & inhibitors / Q000378:metabolism*; D018844:Cyclin-Dependent Kinases / Q000378:metabolism; D016193:G1 Phase / Q000235:genetics; D005786:Gene Expression Regulation; D006801:Humans; D009369:Neoplasms / Q000378:metabolism* / Q000628:therapy; D015513:Oncogene Proteins / Q000378:metabolism; D010766:Phosphorylation; D016160:Retinoblastoma Protein / Q000378:metabolism; D016196:S Phase / Q000235:genetics; D014452:Ubiquitins / Q000378:metabolism
D000970:Antineoplastic Agents; D015513:Oncogene Proteins; D016160:Retinoblastoma Protein; D014452:Ubiquitins; D019938:Cyclin D1; D018844:Cyclin-Dependent Kinases